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Abstract
Background: Serum carcinoembryonic antigen (sCEA) level might be an indicator of disease. Indeed, an elevated sCEA level
is a prognostic factor in colorectal cancer (CRC) patients. However, the genetic determinants of sCEA level in healthy and
CRC population remains unclear. Thus we investigated the genetic markers associated with elevated serum sCEA level in
these two populations and its clinical implications.
Methods and Findings: Genome-wide association study (GWAS) was conducted in a cohort study with 4,346 healthy male
adults using the Illumina Omni 1 M chip. Candidate SNPs associated with elevated sCEA levels were validated in 194 CRC
patients on ABI Taqman platform. Eight candidate SNPs were validated in CRC patients. The rs1047781 (chr19- FUT2) (A/T)
was associated with elevated sCEA levels, and rs8176746 (chr9- ABO) was associated with the regional lymph metastasis in
the CRC patients. The preoperative sCEA level was a risk factor for tumor recurrence in 5 years after operation (OR = 1.427,
95% CI: 1.005&1.843, P = 0.006). It was also one of the risk factors for regional lymph node metastasis (OR = 2.266, 95% CI:
1.196&4.293, P = 0.012). The sCEA level in rs1047781-T carriers was higher than that in the A carriers in CRC patients without
lymph node metastasis (P = 0.006). The regional lymph node metastasis in patients with homozygote AA of rs8176746 was
more common than that in the heterozygote AG carriers (P = 0.022). In addition, rs1047781-AT and TT CRC patients
exhibited a worse disease-free survival than AA genotype carriers (P = 0.023).
Conclusions: We found candidate SNPs associated with elevated sCEA levels in both healthy males and CRC population.
Rs1047781 (chr19- FUT2) may be the susceptible locus for recurrence of CRC in a population from Southern China.
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in Oncology. Written informed consent was required from all
patients. They were followed up to 51 months, and by the end
there were 57 patient with tumor recurrence (median survival: 48
months; range: 7&62 months). This study was approved by the
ethics committee of Guangxi Medical University. Baseline
characteristics of participants were summarized in Table S4.
Genotyping of candidate SNPs in CRC patients. Nine
candidate SNPs from the 25 SNPs that reached genome-wide
significance were selected for genotyping in CRC patients:
rs8176746 (chr9- ABO), rs1047781 (chr19-FUT2), rs3760775
(chr19-FUT6), rs441810 (chr21-FAM3B), rs12608544 (chr19DBP), rs3786749 (chr19- SULT2B1), rs2071699 (chr19- FUT1),
rs507666 (chr9- ABO) and rs687289 (chr9- ABO).
DNA was extracted from the colon mucous membranes using a
DNA Extraction Kit (Tiangen, China). PCR platform (STEPONE
PLUS ‘TM, Applied Biosystem. Foster city, CA) was used to
conduct allele’s genotyping. Automatic SNP genotyping was run
by StepOne Plus ‘TM version 2.2 system (Applied Biosystem.
Foster city, CA); the quality control criteria used were the same as
that in GWAS. The details of experiment are described in Text S1
and Table5.
Chemotherapy. According to the risk for post-operation
recurrence, some patients at stage IIand all stage III patients
received at least one cycle of Oxalipatin, Fluorouracil, and
Leucovorin (FOLFOX regiment) as adjuvant treatment in our
study. Patients at age $70 years did not receive adjuvant
treatment. Adverse effects were assessed using the Common
Toxicity Criteria of National Cancer Institute version 2.0.
Chemotherapy was stopped when there was cardiac or neurocerebellar adverse effects or grade 3 or 4 allergic reaction.
Follow-up. Patients in our study were assessed every six
months after operation. The recurrence was determined on the
basis of physical examination, chest radiography, abdominal
ultrasonography or computer tomography, colonoscopy, CEA
level detection, and if necessary, cytologic analysis or biopsy. The
cut-off date of the analysis was June 20, 2013; duration of followup was defined as the number of months from operation to the
cut-off date. The disease-free survival was measured from the time
of operation to the recurrence of tumor.
Statistical analyses. Nonparametric statistics was used in
univariate analysis. Multivariable models were constructed by
Logistic regression analysis. Kaplan-Meier estimators were applied
in calculating survival function; the log-rank test was used to
determine the survival differences among individual groups. The
SPSS v.17.0 program was used for analysis and a P value ,0.05
was considered statistically significant.

Introduction
Colorectal cancer (CRC) is the fourth most common cancer in
males and the third most common in females worldwide. It
accounts for an estimated 1.2 million new cancer cases and over
630,000 cancer deaths per year [1]. Incidence and mortality of
CRC rose rapidly in China since the 1990s [2]. Sporadic CRC is
the most common that occurs in the absence of family history,
generally affects older population, and usually presents as an
isolated colon or rectal lesion. Curative surgery is the most
important approach of treatment. However, 5-year survival after
resection is merely 60.8 % in China. Approximately 50% of these
patients would undergo tumor relapse and die [3]. The prognosis
was affected by factors such as cigarette smoking, age, gender and
race, duration of symptoms, presence of bowel obstruction, tumor
location, blood transfusion and the quality of surgical intervention
[4].
Carcinoembryonic antigen (CEA) level might be elevated in the
serum of people with non-neoplastic diseases, malignant tumors or
cancers. Thus an elevated CEA level is an independent prognostic
factor in CRC patients regardless of its Duke’s stage and
histological grade [5]. In the healthy population, serum CEA
levels could be affected by environmental and genetic factors such
as age, smoking, drug, disease, gender and race [6–8]. However, in
patients with CRC, additional mechanisms determining serum
CEA level remain unclear.
Genome mutations associated with the elevated CEA level in
CRC is present in the tumor itself, so such mutations could not be
served as a genetic marker for CEA level for diagnostic purposes
[9]. Therefore, this study was conducted in two phases: at phase
one, a genome-wide association study was conducted to identify
the loci associated with the serum level of CEA in healthy Chinese
men from a cohort that participated in the Fangchenggang Area
Male Health and Examination Survey (FAMHES) (this part has
been merged with other cohorts and partly published elsewhere
[10], [11]). At phase two, the association between candidate SNPs
found from phase one GWAS and preoperative CEA levels and
prognosis of patients with CRC was analyzed. Based on this
design, we tried to explore in this study the association between
polymorphisms and the prognosis of CRC after radical operation
on account of susceptible loci associated with elevated sCEA level.

Methods
Phase one study
A genome-wide association study was conducted to identify the
loci associated with the serum level of CEA in healthy Chinese
men from FAMHES cohort (The experiment and results were
described in Text S1, Tables S1, S2, S3, and Figure S1).

Results
Factors affecting sCEA levels in healthy population

Phase two study

In General Linear Regression model, Age (Beta = 0.003, P,
0.0001), total quantity of cigarettes (Beta = 0.004, P,0.001) and
BMI (Beta = -0.005, P = 0.006) was significantly associated with
CEA level (Table 1). R2 of this model was 0.07 (F = 51.834,
ANOVA).

One hundred
and ninety-four colorectal carcinoma patients who met the criteria
for enrollment were recruited from patients undergoing curative
resection between March 2008 and February 2012 at the
Department of Anal and Colorectal Surgery, 1st Affiliated Hospital
of Guangxi Medical University. All tumors in the study were
adenocarcinoma, and the pathological diagnoses were confirmed
independently by two expert gastrointestinal pathologists. All
patients were absent of symptoms such as severe bleeding, bowel
obstruction or infection. None of them had any preoperative
radio-chemotherapy. All patients were treated with postoperative
chemotherapy protocol based on NCCN Clinic Practice Guideline
Patients with sporadic colorectal cancer.

PLOS ONE | www.plosone.org

Genotyping in CRC patients
The candidate SNPs used to genotype for 194 CRC patients
with adenocarcinoma and the genotyping results were listed in
Table S6.
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Table 1. Multiple linear regression analysis of the factors affecting sCEA levels in FAMHES participants.

Variables

B

Beta

p

95% C.I for B

Adjusted R2

(constants)

1.365

0.043

,0.0001

0.19&0.357

0.070

Age

0.003

0.147

,0.0001

0&0.004

Total quantity of cigarettes

0.004

0.175

,0.0001

0&0.005

BMI

-0.005

-0.06

0.006

-0.008&0

B: unstandardized coefficients; Beta: standardized coefficients. Data of CEA values had been log-transformed for normal distribution. Regression model (F-value of
ANOVA: 51.384; p,0.01).
doi:10.1371/journal.pone.0097923.t001

respectively). The J-T test showed that the TT allelic subgroup
had a higher sCEA level while the AA had the lowest (P = 0.011).
Other candidate SNPs were not associated with CEA levels in
CRC patients (Table 3). For rs1047781 (chr19- FUT2), the allelic
genotype TT was associated with the highest sCEA level, and the
difference in the sCEA level between allele T carriers and
homozygote AA was significantly different (AA vs. AT: P = 0.008;
AA vs. TT: P = 0.006; AT vs. TT: P = 0.787; respectively)
(Table 4).

Risk factors for elevated CEA levels in CRC patients
The univariate analyses revealed that the preoperative CEA
level was significantly different by status of regional lymph nodes
and distant organ metastases (positive vs. negative: 5.36 vs.
3.41 ng/ml; P = 0.011; 11.87 vs. 3.60 ng/ml; P = 0.033. respectively). The preoperative CEA level was also not associated with
factors such as age, gender, cigarette smoking, alcohol drinking,
tumor size and cell differentiation (Table 2).
In patients without regional lymph nodes metastasis, subgroups
with rs1047781 (chr19- FUT2) AT and TT allele had a
significantly higher CEA level than the AA carriers
(AA:1.73 ng/ml, AT: 3.49 ng/ml and TT: 4.11 ng/ml;
P = 0.006). However, the difference was not significant in the
CRC patients with lymph node or distant organ metastasis (AA vs.
AT: P = 0.686, AA vs. TT: P = 0.202, AT vs. TT: P = 0.139,

Risk factors for tumor metastasis in CRC patients
The rate of regional lymph node (RLN) metastasis in the allelic
subgroup AT was the highest in the three subgroups of rs1047781
(AA: 12.8%, AT: 19.6%, TT: 9.0%; AA vs. AT: P = 0.961, AA vs.
TT: P = 0.046, AT vs. TT: P,0.001; respectively). The rates of

Table 2. Univariate analysis of factors affecting the preoperative CEA levels in CRC patients.

n

sCEA Level (ng/ml)1

P value

$60

93

3.30

0.077

,60

96

4.34

Male

117

3.67

Female

72

4.19

Yes

45

4.29

No

145

3.49

Yes

41

4.61

No

149

3.49

$5

94

3.52

,5

94

4.66

Well

9

3.43

Moderately

153

3.80

Poorly

21

3.49

Yes

16

11.87

no

174

3.60

yes

77

5.36

no

112

3.41

Variables
Age (yrs.)

Gender

Cigarette smoking

Alcohol drinking
Tumor size(cm)2

Tumor Differentiation

Distant organ metastasis

Regional lymph nodes metastasis

Depth of tumor invasion

I

1

-

II

44

2.26

III

60

3.54

IV

1

-

0.689

0.606

0.202

0.194

0.719

0.033

0.011

0.129

1

The CEA level was represented by median.
The tumor size was represented by the max diameter of primary tumor. The patients with regional lymph nodes metastases or distant metastases were excluded in this
analysis.
doi:10.1371/journal.pone.0097923.t002
2
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4
25

GG

3.67

6.09

12.86

4.11

-

12.2

13.5

5.67

5.36

7.24

4.37

12.27

8.13

4.87

6.82

6.24

5.73

5.83

17.98

3.67

5.23

3.43

8.29

6.39

-

0.269

0.214

0.644

0.158

0.687

0.947

0.186

0.360

0.179

(sCEA)

P

3

2

The patients with distant metastases were excluded.
CEA levels were represented by median.
St. J-T statistic was represented using the standard statistic of Jonckheere-Terpstra test.
doi:10.1371/journal.pone.0097923.t003

1

24

AG

ABO

31
14

GG

AA

rs687289

0

AG

21

AA

ABO

7

GG

rs507666

21

AG

FAM3B

39
35

GG

AA

rs441810

24

AG

FUT1

4
3

TT

AA

19

CT

18

rs2071699

ABO

CC

30

GG

rs3786749

30

AG

DBP

13
8

TT

AA

rs12608544

22

GT

FUT6

15
33

TT

GG

rs3760775

38

AT

24

AA

FUT2

1

GG

rs1047781

18

AG

ABO

3.16

(ng/ml)
5.83

46

sCEA levels

AA

n

gene

allele

rs8176746

SNP

2

Metastasis (yes)

3

0.165

-

0.644

0.437

0.368

0.761

0.161

0.369

0.222

(St.J-T )

P

42

47

15

52

0

39

7

37

51

55

43

4

12

28

35

45

41

19

11

45

49

23

48

34

1

33

66

n

3.61

2.39

2.52

3.19

-

2.52

9.66

2.65

3.02

2.52

4.11

8.69

2.36

3.22

2.32

2.52

4.58

2.69

3.80

2.85

2.85

4.11

3.49

1.73

-

2.65

2.85

(ng/ml)

sCEA levels2

Metastasis (no)

0.419

0.900

0.261

0.075

0.264

0.040

0.750

0.006

0.705

(sCEA)

P
3

0.517

-

0.730

0.035

0.912

0.354

0.466

0.010

0.557

(St.J-T )

P

Table 3. Association between candidate SNPs and preoperative CEA levels in CRC patients stratified by status of regional lymph nodes metastasis.1

0.398

-

0.739

0.814

0.912

0.763

0.279

0.753

0.022

(metastasis)

P
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5

3

2

The values of CEA levels and times were represented by median values, and the range of sCEA level is shown.
St. J-T statistic was represented using the standard statistic of Jonckheere-Terpstra test.
The distant organs included liver, lung and omentum.
4
The rate of tumor lymph node metastasis was adjusted.
5
The statistical evaluation for CEA levels was performed by Mann-Whitney U test.
doi:10.1371/journal.pone.0097923.t004

1

0.006
0.787

AA vs TT

AT vs TT

4.11 (0.96-21.97)

3.49 (0.50-282.76)

0.008

23

TT

0.006

AA vs AT

48

AT

metastasis

1.73 (0.50-21.05)

0.808
34

AT vs TT

AA

0.114

AA vs TT

51.75 (3.85-762.70)

0.304

0.368

4

17.53 (0.87-150000)

2.83 (2.10-20.87)

3.43 (0.92-22.740)

AA vs AT

TT

8

4

15

Non-

metastasis

AT

3

organ

0.139

AT vs TT

AA

0.202

AA vs TT

Distant

0.686

TT

AA vs AT5

metastasis

0.287

nodes

8.29 (0.50-150000)

6.39 (1.10-110.06)

24

AT

38

AA

(sCEA)

P

lymph

sCEA level1

Regional

(n)
(ng/ml)

Allele

Type

Metastasis
2

0.01

0.167

0.377

(St.J-T )

P

4(1.86%)

8(4.04%)

4(2.60%)

15(9.2%)

37(19.6%)

24(12.6%)

yes(N,%)4

Metastasis status

Table 4. Association between RLN metastasis and preoperative sCEA levels (stratified by rs1047781 genotypes).

37(19.9%)

81(43.3%)

54(28.2%)

26(13.1%)

50(27.8%)

32(17.8%)

no (N, %)

0.888

0.607

0.651

0.860

,0.001

0.046

0.961

0.784

P
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Table 5. Logistic regression analysis of the risk factors influencing regional lymph nodes with tumor metastasis before radical
operation.

variables

B

S.E

OR

95%C.I. for OR

p

T stage

0.613

0.218

1.847

1.203&2.835

0.005

Preoperative CEA levels

0.818

0.326

2.266

1.196&4.293

0.012

Ages

-0.880

0.326

0.415

0.215&0.801

0.009

constant

-2.198

0.365

0.111

0.001

Variables in the equation included age, gender, tumor size, tumor T stage, preoperative CEA levels and histological grade.
doi:10.1371/journal.pone.0097923.t005

(P = 0.458), we also found a similar trend in the CRC patients (B.
A) (Figure 6, 7).

distant organ metastasis in the three allelic subgroups of rs1047781
were not significantly different (AA vs. AT: P = 0.651; AA vs. TT:
P = 0.607; AT vs. TT: P = 0.888, respectively) (Table 4). The
frequency of RLN metastases was significantly different in the
allelic subgroups of rs8176746 (chr9-ABO) (P = 0.022).

Discussion
Factors affecting Serum CEA levels in the healthy
population

Risk factors for disease-free survival in CRC patients

In support of a previous report on healthy volunteers in the
United States, we found that cigarette-smoking is associated with
CEA levels [12]. Furthermore, when the smoking status is further
quantified by the amount of cigarettes (pack per year), a trend in
the association between smoking grading and CEA levels was
statistically significant. Long term exposure to carcinogens from
cigarette-smoking contributes to a variety of malignancies, such as
non-small- cell lung cancer, pancreatic cancer and oral cancer
[13], [14]. In addition, some studies have reported that an elevated
CEA level associated in such malignancies [15]–[17]. Therefore
the elevated CEA level might reflect the risk for tumor.
It has been reported that CEA levels increase with aging in
France and Netherland populations [18], [19]. However, the trend
for higher CEA levels in elders does not necessary correlate with a
higher risk for non-neoplastic diseases or cancer [20]. Our finding
of the association between elevated CEA level and aging in men
from the Fangchenggang area support the notion that age is an
independent factor influencing the CEA level in spite of the
disparity of population and area. Interestingly, in male smokers,
the contribution of age to CEA levels was attenuated.
We found in this study a negative correlation between BMI and
CEA level in the healthy male Chinese. It is therefore necessary to
consider BMI when conducting GWAS in this population.

Logistic regression analysis revealed that age, preoperative CEA
level and T stage (tumor invasion) were risk factors for regional
lymph nodes metastasis (Table 5). The preoperative CEA level
was also the risk factor for tumor recurrence in 5 years after radical
operation (Table 6). The probability of survival was higher in the
group of regional lymph nodes negative than those positive for
metastasis, and was lower in the group with a preoperative CEA
level of $5 ng/ml than those with ,5 ng/ml. The differences
were statistically significant (Figure 1, 2). SNPs associated with
the CEA level and regional lymph metastasis, rs1047781 (chr19FUT2) and rs8176746 (chr9- ABO), were not the independent
contributors to disease-free survival (Figure 3, 4). We used the
combination of SNPs (rs1047781 and rs8176746) as the genetic
marker in survival analysis and the disease-free times was
significantly different between rs1047781-AA and rs1047781
(AT+TT) genotype carriers among rs8176746 (AA+AG) carriers
(P = 0.023) (Figure 5). However, the difference was not determined
among the rs8176746-GG carriers.

ABO genotypes and serum CEA levels
The distribution of CEA levels by ABO blood allelic type was
significantly different in healthy people (BB.BO.AB.OO.
AO.AA, P = 1.47E-26). Although it is not statistically significant

Table 6. Logistic regression analysis of risk factors influencing 5-yr recurrence in CRC patients.1

Variables

B

S.E

OR

95%C.I. for OR

p

Tumor site

-0.492

0.317

0.612

0.329&1.138

0.121

Macropathological type

-1.122

0.709

0.326

0.081&1.307

0.114

Cell differentiation

-0.433

1.108

0.649

0.074&5.696

0.696

Lymph node metastasis

1.103

0.966

3.014

0.454&20.002

0.253

Chemotherapy

-0.811

1.070

0.414

0.051&3.373

0.410

Tumor size

1.361

0.933

3.898

0.626&24.276

0.145

Gender

0.950

0.890

2.586

0.452&14.801

0.286

Age

0.013

0.03

1.013

0.956&1.073

0.670

Preoperative CEA levels

0.356

0.131

1.427

1.005&1.843

Constant

-0.350

3.457

0.704

0.006
0.919

1
The patients with distant organ metastases were excluded.
doi:10.1371/journal.pone.0097923.t006
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Figure 1. Tumor-free survival analysis of CRC patients stratified by regional lymph nodes. The tumor-free time was different between
CRC patients with and without lymph node metastases (p,0.001).
doi:10.1371/journal.pone.0097923.g001

positive or negative for HBsAg. Therefore we did not exclude the
samples positive for HBsAg from the GWAS analysis. An
increased level of CEA has been found in patients with alcoholic
liver diseases or patients with disorders of respiratory and/or
gastrointestinal tracts [26]–[28]. However, the association between
alcohol-drinking and CEA levels was not conclusive in this study.
Therefore, alcohol-drinking is not a justification factor in the
GWAS analysis. It has been reported that the serum levels of CEA
varied among different ethnic-groups [29]. To exclude ethnicspecific genetic factors, we also limited the number of Han
participants in GWAS.
Of note, we found that age, cigarette smoking and obesity to be
the epidemiology factors affecting serum CEA levels. Nevertheless,
the power of the lifestyle or environmental factors in the model

Similarly, Park JS et al. reported that increased BMI is associated
with lower CEA concentrations in CRC patients [21]. Epidemiological studies have also found an association between obesity and
colorectal cancer [22]. In vitro studies have revealed that the
adipocyte could promote the growth of several colon cancer cell
lines [23]. Therefore it has been hypothesized that although the
CEA is produced by epithelial cells, adipose tissue could affect the
secretion of CEA in other tissues via various cytokines and
adipocytokines.
HBV infection is associated with the risk of hepatocellular
carcinoma [24]. However, there is no direct evidence of
association between HBV infection and digestive malignancies
such as pancreatic cancer and gastrointestinal cancer [25]. In this
study, statistical analysis showed that there was no significant
difference in the serum CEA levels between groups that are

PLOS ONE | www.plosone.org
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Figure 2. Tumor-free survival analysis of CRC patients stratified by preoperative sCEA levels. The tumor-free time was different between
CRC patients with preoperative CEA levels at ,5 and $5 ng/ml (p = 0.001).
doi:10.1371/journal.pone.0097923.g002

was weak because the coefficient of determination was merely
0.070.

RPL18, FAM83E are located in regions 19p13.3 and 19q13,
whereas ABO is located in 9q34.2. FUT1, FUT2, FUT3, FUT6
and ABO are genes involved in the biosynthesis pathway of ABH
and Lewis histo-blood group antigens. The five genes encode
glycosyltransferases that catalyze the stepwise addition of specific
monosaccharide unit in the biosynthesis process.
The strongest CEA level-associated SNP was rs1047781 at
19q13, a missense change (A-.T, Ile-.Phe) within the FUT2
gene that encodes a fucosyltransferase catalyzing the production of
the H antigen and determines the secretion status of the ABO and
Lewis histo-blood group antigens. It was reported that the T allele

Genetic variant associated with CEA level in healthy
populations
There were 25 SNPs associated with CEA levels at the genome
wide level based on the analysis using the Multiple Linear
Regression model. The biological functions of these SNPs were
listed in Table S8 and genes involved (except for rs8111500) were
FUT1, FUT2, FUT3, FUT6, ABO, DBP, CA11, RPL18, SULT2B1,
and FAM83E. The genes FUT1, FUT2, FUT3, FUT6, DBP, CA11,
PLOS ONE | www.plosone.org
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Figure 3. Tumor-free survival analysis of CRC patients stratified by rs1047781. With rs1047781 (chr-19 FUT2), the disease-free time of CRC
patients grouped by allelic genotypes (AA, AT and TT) was not significantly different (p = 0.066).
doi:10.1371/journal.pone.0097923.g003

We found eight SNPs located in the ABO gene, encoding an
acetyl-galactosaminyltransfer- ase that determines the ABO blood
types. Based on the data from Seattle SNPs (http://pga.mbt.
washington.edu) as well as the Blood Group Antigen Mutation
Database (www.ncbi. nlm.nih.gov), an associated study revealed
that rs507666 is a surrogate for type A1 histo-blood group antigen,
rs687289 is a marker for the O allele, rs8176746 is a marker for
the B allele and rs8176704 is a marker for the A2 allele [33]. This
interesting finding might support the association between CEA
levels and ABO gene in CRC patients; this result is shown in
Figure 6 and 7.
Furthermore, the ABO histo-blood group type has been
associated with a series of diseases characterized by elevated level
of serum CEA, such as Helicobacter pylori infection, cancer of the
gastro-intestinal tract, breast cancer, and pulmonary cancer [34],

of this SNP represents a de facto inactivated mutant of the FUT2
enzyme and was causally associated with the non-secretor
phenotype in a Japanese population [30]. But the direct
experimental evidences supporting the biology association between various forms of ABO, Lewis histo-blood group antigens
and CEA levels are absent. Some studies have provided indirect
evidences that the A antigen moiety coded by ABO is present on
CEA molecules [31], and that the determinants of A, B and H
antigens and of CEA shared the same glycoprotein carrier
molecules [32]. Thus it may be speculated that the genetic
polymorphisms of various CEA antigen-synthesizing glycosyltransferases may modify the sugar groups of the CEA molecules,
leading to varying stabilities of CEA molecules in the blood, or
alternatively resulting in different detection rates by the given CEA
measurement method.
PLOS ONE | www.plosone.org
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Figure 4. Tumor-free survival analysis of CRC patients stratified by rs8176746 genotypes. With rs8176746 (chr-9 ABO), the disease-free
time of CRC patients grouped by allelic genotypes (AA and AG) was not significantly different (p = 0.366). Subjects with genotype GG were excluded
(n = 2).
doi:10.1371/journal.pone.0097923.g004

[35]. The ABO blood type group exhibiting a high level sCEA
might suggest a high risk for these diseases in the ABO carrier
population [36], [37]. Because of the lack of knowledge of CEA
molecular synthesis, it is hard to do further bioinformatics analysis
in addition to that for ABO and FUT genes.
The purpose of our phase one study was to find loci to be used
to select candidate loci for SNP genotyping in CRC patients. We
inferred that SNPs were associated with elevated sCEA levels in
healthy and CRC population from the same region. Therefore
candidate SNPs were determined based on rank of genome-wide
P-value and location of genes relevant to ABO blood type.
Rs8176746, rs376077, rs12608544, rs3786749, rs2071699,
rs441810 and rs507666 were subsequently included in the
genotyping of CRC patients.

PLOS ONE | www.plosone.org

Genetic variation associated with serum CEA levels in
CRC patients
In order to estimate the heterogeneity, potential non-genetic
confounders affecting CEA levels in healthy populations were
analyzed in CRC patients at first and revealed that the status of
lymph node metastasis was a significant contributor. Stratification
analysis showed that rs1047781 (chr19- FUT2) was the associated
loci in CRC patients. This suggests that there might be
confounders in addition to the status of lymph node metastasis.
In accordance with the results from the GWAS analysis in healthy
population, the rs1047781 was a susceptible locus for elevated
CEA level in CRC patients. In healthy population, the CEA level
of AA genotype was the lowest and TT was the highest (data have
been adjusted for confounders). Similarly, genotype AA carriers
had the lowest CEA levels in the CRC patients without tumor
metastasis. The allele T (thymine) to A (adenine) in rs1047781 is a
missense mutation. The other study in FAMHES showed
10
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Figure 5. Tumor-free survival analysis of CRC patients stratified by rs1047781+rs8176746 genotypes. Subjects were divided into 2
groups by genetic maker (rs1047781+rs8176746). Group 1 was rs1047781 (AA) +rs8176746 (AA+AG) and group 2 was rs1047781 (AT+TT) +rs8176746
(AA+AG). The disease-free time of subgroups was significantly different (p = 0.023).
doi:10.1371/journal.pone.0097923.g005

different prognosis from those with the AA genotype. The results
suggest that CDX2 might be inactive in allele T carriers, resulting
in a difference of expression between FUT2 and CEA. The allele
T carrier might be susceptible to tumor metastasis at the early
stage of CRC and to tumor recurrence in the future. It was
reported that b1, 3- Galactosyltransferase is down-regulated in
colon adenocarcinomas and causes CEA express with absence of
type 1 chain [41], but the relation between FUT2 and CEA was
still unknown. Therefore laboratory evidence is needed to prove
whether this polymorphism is biologically functional [42].

rs1047781 to be a locus associated with vitamin B12 levels in
healthy people [38]. However, this was not determined in CRC
population. So far, there has been no convincing evidence about
Vitamin B12 and any other lifestyle factors affecting CRC
recurrence and survival [39]. An in vitro experiment showed that
the CDX2 gene is associated with the increase in sLex/a expression
and suppression of FUT2 in colon cancer cells during EGF/
bFGF-induced epithelial–mesenchymal transition (EMT) [40].
EMT is a critical phenotypic alteration in metastatic cancer cells.
We observed that AT and TT genotypes of rs1047781 (FUT2),
and not the AA genotype, are associated with higher serum CEA
levels. Interestingly, the CRC patients with T allele exhibited a
PLOS ONE | www.plosone.org
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Figure 6. Distribution of serum CEA levels by ABO allelic genotypes in the healthy population. The CEA levels of male FAMHES subjects
grouped by ABO groups genotypes were significantly different (p = 1.47E-26).
doi:10.1371/journal.pone.0097923.g006

$75 yrs.) is the important risk factor for patients with CRC
regardless of the type of therapy and grade of tumor stage [45].
For patients who underwent curative resection, the prognosis of
elderly patients ($75 yrs.) was also worse than the younger
(25&75 yrs) [46]. However, we did not find this association in our
population. Prospective studies suggested that cigarette smoking is
associated with the mortality of CRC [47]. Proposed mechanism
of this pathogenesis is through the DNA damage caused by
carcinogens of cigar smoke [48,49]. Obesity and the accompanying chronic systemic inflammation and metabolic alteration are
risk factors for CRC [50]. It was reported that gender is also a
potential factor affecting the prognosis of CRC but only in patients
at age ,40 yrs [51]. Thus we considered that it is inclusive and
did not take it as a confounder in relevant analysis.

Risk factors for preoperative CEA levels and tumor
recurrence in CRC patients
The age, cigarette smoking, alcohol drinking and obesity were
confounders for the serum CEA levels in healthy people. Among
CRC patients, the status of metastasis in regional lymph nodes and
distant organs were main confounders of preoperative CEA levels
in our study. To test if tumor size is a confounder [43], in our
study, the association between tumor size and pre CEA levels was
examined yet the association was not significant (see Figure S2).
BMI is affected by advancing age more than 20 yrs old and it is
not an independent variety in our analysis [44]. Literatures
reported that age, obesity, alcohol intake and cigar smoking were
independent risk factors for the prognosis of CRC. Age (especially
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Figure 7. Distribution of serum CEA levels by ABO allelic genotypes in CRC patients. The serum CEA levels of patients with CRC grouped
by blood group allelic genotypes were represented by median and there were not significantly different (x2 = 3.63, p = 0.458). Geneotype AO was
absent; A1 and A2 were included in A allelic type. The ABO blood type was determined before operation.
doi:10.1371/journal.pone.0097923.g007

rs1047781-TT carriers had lower CEA levels and fewer RLN
metastases, supporting the association between CEA levels and
prognosis. Since rs8176746 was associated with lymph node
metastasis, the combination of rs1047781 and rs8176746 as
genetic markers of disease-free survival was applied for further
analysis. As suggested by Figure 3, rs1047781 (AT+TT) carriers
had worse disease-free survival than the AA carriers. It is in
accordance with the higher CEA levels among mutant type
rs1047781 carriers.
Although these SNPs might associate with tumor recurrence in
CRC, the overall survival of CRC patients was not significantly
different in 5 years when grouped by rs1047781 or rs8176746
(Figure S4, S5). This suggests that overall survival of CRC patients
was affected by other factors excepted for tumor recurrence.
Therefore it is worthwhile to test if rs1047781 is a prognostic
marker of tumor recurrence among CRC patients.

Genetic variant associated with tumor recurrence in CRC
patients
The elevations of CEA levels in healthy and CRC populations
might suggest biological relationship between synthesis of ABH
antigen and CEA. Although the preoperative CEA levels were
associated with ABO allelic genotypes and tumor recurrence, the
disease-free times of groups with blood types A and O were not
significantly different in survival analysis (Figure S3). This result
also suggested that the ABO blood types were not biomarkers of
tumor recurrence prediction.
Logistic regression model showed that the preoperative CEA
level, age and depth of tumor invasion were risk factors influencing
RLN metastasis. Also, the preoperative CEA level was a significant
factor contributing to the risk of tumor recurrence in 5 years. It is
therefore interesting to explore the association between sCEArelevant SNPs and lymph node metastasis. As shown in Table 3,
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Overexpression of the CEA gene (and CEACAM6) has been
found in a series epithelial malignancies including CRC [52], [53].
This could disrupt the colonocyte differentiation and promote
colon carcinogenesis [54]. Higher preoperative sCEA levels were
associated with higher risk of CRC recurrence after operations.
Thus the preoperative sCEA level could be served as an
independent prognostic factor [55], [56], [57]. The mutation in
the tumor cell’s CEA gene (PELPK motif; Pro-Glu-Leu-Pro-Lys)
might induce high CEA levels by its hepatic clearance; mutation in
the PELK motif could alter structural stability and binding affinity
to Kupffer’s cell receptor in the liver [58]. In addition, this binding
results in the release of a series of cytokines that have the potential
to activate hepatic sinusoidal endothelium [59]–[61]. These
observations imply that the CEA could be a facilitator of hepatic
metastasis, although direct association between CEA level and
lymph node metastasis is absent.
Another study indentified rs10318 (GREM1), rs6983267
(POU5F1P1, DQ515897, MYC) and rs4464148 (SMAD7) associated with clinic outcome in patients with stage II and stage III
CRC treated with 5-FU-based adjuvant chemotherapy [62].
GREM1, BMP2 and SMAD7 are signaling molecules in the TGFb pathway. Overexpression of TGF-b signaling genes has been
found in the progression of CRC [63]. Given the complex process
of CRC recurrence and metastasis, this finding suggested there are
other genetic risk factors. Interestingly, it was reported that CEA
could interact with TGF-b receptor and inhibits TGF-b signaling
directly; even enhance the survival of colorectal cancer cells in
local colonization in animal study [64].

mechanisms are definitely needed. (3) Because the samples
included in our study were limited to Guangxi province, a region
in southern China, we have yet to determine the significance of
such associated SNPs in populations of other regions.

Supporting Information
Figure S1

Figure S2 Scatter plots of association between tumor
size and sCEA levels in CRC patients. The CRC patients
without regional lymph node and distant organ metastasis were
included in analysis; tumor size was represented by max tumor
diameter.
(TIF)
Figure S3 Survival analysis for disease-free times of
CRC patients grouped by A and O blood type. The
difference of disease-free times was not significantly different
(p = 0.391).
(TIF)
Figure S4 Overall survival of CRC patients grouped by
rs8176746. In rs8176746 (chr-9 ABO), overall survival of CRC
patients grouped by allelic genotypes (AA, AG+GG) was not
significantly different (p = 0.084).
(TIF)
Figure S5 Overall survival of CRC patients grouped by
rs1047781. In rs1047781 (chr-19 FUT2), the overall survival of
CRC patients grouped by allelic genotypes (AA, AT +TT) was not
significantly different (p = 0.165).
(TIF)

Adjuvant therapy of CRC
In our study, some CRC patients with stage II and all the
patients with stage III received FOLFOX regiment as adjuvant
treatment [65], [66]. However, chemotherapy itself was not
associated with tumor relapse in the five years of follow-up. The
benefit of adjuvant chemotherapy for patients with stage II CRC is
still debatable [67]. As suggested by clinical trials the disease-free
survival of 3 years follow-up might be appropriate index in
patients with stage II CRC when treated by fluorouracil [68].
Thus the follow-up time was up to 4 years in our study. In a metaanalysis of adjuvant therapy and survival among patients with
resected CRC, the longer time to adjuvant therapy was associated
with worse survival [69]. It suggested that optimal timing of
adjuvant therapy was an important factor and needed to be
evaluated in analysis.

Table S1 Demographics of the participants from FangChengGang Area Male Health Examination Survey.
Subjects of Han nationality were included in analyses.
(DOC)
Table S2 Univariate analysis of factors affecting sCEA
levels in FAMHES participants. CEA values are presented as
Mean6S.D. The value of CEA had been log-transformed to fit for
normal distribution in analysis.
(DOC)
Table S3 SNPs associated with sCEA levels in GWA
study. a. Genomic position is based on NCBI build 36. b. a/A:
minor allele/major/allele. c. MAF indicate the minor allele
frequency for allele a. d. aa indicates serum complement levels for
homozygous carriers of minor alleles, Aa indicates for heterozygous carriers, and AA indicates for homozygous carriers of major
alleles. e. P values are adjusted for age, folic acid level and BMI.
(DOC)

Summary
We reported in this study the genetic variations associated with
CEA levels in CRC population. We found that the rs1047781 is
the susceptible locus for elevated sCEA level whereas rs8176746 is
associated with the status of regional lymph node metastasis. The
elevated sCEA level and status of lymph node metastasis are risk
factors for tumor-recurrence after radical operation. The SNP
rs1047781 might be a predictor for tumor recurrence in TNM
stage II and III CRC patients. The contribution of rs8176746 was
not addressed in this study.
A number of limitations of our study must be addressed: (1) In
addition to CRC, elevated sCEA levels have been reported among
cholangio-carcinoma, pancreatic carcinoma and breast cancer
patients. Therefore, it is interesting to explore the influence of the
candidate SNPs we found in this study in these malignancies. (2)
Although candidate SNPs such as rs1047781 is located in the
encoding region, its biological function is still unknown based on
existing evidence. Therefore experiments exploring the regulatory
PLOS ONE | www.plosone.org
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(TIF)

Table S4 Baseline Characters of CRC Patients.

(DOC)
Table S5 Assay ID of SNPs genotyped in CRC patients.

(DOC)
Table S6 Summary of the SNPs genotyping in CRC
patients. There were 194 CRC patients with adenocarcinoma in
analysis.
(DOC)
Table S7 Biological functions of associated SNPs.

Dataset: http://www.ncbi.nlm.nih.gov/projects/SNP/.
(DOC)
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